Scientific documents library

This information card presents how the WDF and the WPC measurement channels, by using their unique reagent systems, allow conclusion on cell maturity, activation state of a cell, and suspected cell malignancies using different cell examples.

This clinical infromation card explains functional iron deficiency (FID) and the advantages of the parameter RET-He (reticulocyte haemoglobin equivalent) as it reflects the the iron availability for haemoglobination in the bone marrow in real-time. A patient case illustrates how RET-He helps to monitor the iron availability at diagnosis and during treatment of FID.

This lab card illustrates the value of the WPC channel and the Extended Inflammation Parameters. The front side addresses the lab and clinical benefits, the flip side contains technical information.

The lab card describes the differences in the PLT-I (impedance platelet count), PLT-O (optical platelet count) and PLT-F (fluorescence platelet count) measurements and points out suggestions to streamline the platelet workflow using the Thrombopoiesis Workflow Optimisation (TWO) on Extended IPU.

The fluorescence technology and channel-specific reagents of the XN-Series provide much more than just a cell count. Depending on their cell membrane composition, cells are perforated and labelled differently, disclosing information about the cells’ activity, maturity stage, and malignancy. This white paper sheds a light on how the XN measures cell functionality.

Once the analysis results have been technically validated and considered reliable, they can be looked at from a clinical angle to search for suspect results. The task of biomedical validation is to recognise abnormal or conspicuous quantitative results. Based on the findings compiled by the GFHC, there is a new rule set implemented in Extended IPU looking at things such as cut-off values, assessment of previous values or additional patient information. Check out the recommendation from GFHC.

This clinical information card addresses the clinical challenges during haematopoietic stem cell transplantation (HSCT) treatment. The example case of an oncologic patient is described and the benefits of advanced clinical parameters delivered by the haematology analysers are emphasised for all phases of the HSCT treatment: mobilisation, chemotherapy and engraftment.

The first part of this SEED article informs about haematopoietic stem cells, their aetiology and sources as well as the clinical background of haematopoietic stem cell transplantation (HSCT).